Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis.

Khan F, Rahman A, Carrier M, Kearon C, Weitz JI, Schulman S, Couturaud F, Eichinger S, Kyrle PA, Becattini C, Agnelli G, Brighton TA, Lensing AWA, Prins MH, Sabri E, Hutton B, Pinede L, Cushman M, Palareti G, Wells GA, Prandoni P, Büller HR, Rodger MA; MARVELOUS Collaborators.

BMJ. 2019 Jul 24;366:l4363. doi: 10.1136/bmj.l4363.

2.

Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma.

Brighton TA, Khot A, Harrison SJ, Ghez D, Weiss BM, Kirsch A, Magen H, Gironella M, Oriol A, Streetly M, Kranenburg B, Qin X, Bandekar R, Hu P, Guilfoyle M, Qi M, Nemat S, Goldschmidt H.

Clin Cancer Res. 2019 Jul 1;25(13):3772-3775. doi: 10.1158/1078-0432.CCR-18-3470. Epub 2019 Mar 19.

PMID:
30890552
3.

Risk of recurrent venous thromboembolism according to baseline risk factor profiles.

Prins MH, Lensing AWA, Prandoni P, Wells PS, Verhamme P, Beyer-Westendorf J, Bauersachs R, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Kakkar AK, van Bellen B, Pap AF, Homering M, Tamm M, Weitz JI.

Blood Adv. 2018 Apr 10;2(7):788-796. doi: 10.1182/bloodadvances.2018017160.

4.

Long-term risk of recurrence after discontinuing anticoagulants for a first unprovoked venous thromboembolism: protocol for a systematic review and meta-analysis.

Khan F, Rahman A, Carrier M, Kearon C, Schulman S, Couturaud F, Prandoni P, Eichinger S, Becattini C, Agnelli G, Büller HR, Brighton TA, Palareti G, Pinede L, Sabri E, Hutton B, Wells GA, Rodger MA; MARVELOUS Collaborators.

BMJ Open. 2017 Sep 21;7(9):16950. doi: 10.1136/bmjopen-2017-016950.

5.

Thrombocytopenia and CD34 expression is decoupled from α-granule deficiency with mutation of the first growth factor-independent 1B zinc finger.

Rabbolini DJ, Morel-Kopp MC, Chen Q, Gabrielli S, Dunlop LC, Chew LP, Blair N, Brighton TA, Singh N, Ng AP, Ward CM, Stevenson WS.

J Thromb Haemost. 2017 Nov;15(11):2245-2258. doi: 10.1111/jth.13843. Epub 2017 Oct 13.

PMID:
28880435
6.

Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism.

Weitz JI, Lensing AWA, Prins MH, Bauersachs R, Beyer-Westendorf J, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Freitas MCS, Holberg G, Kakkar AK, Haskell L, van Bellen B, Pap AF, Berkowitz SD, Verhamme P, Wells PS, Prandoni P; EINSTEIN CHOICE Investigators.

N Engl J Med. 2017 Mar 30;376(13):1211-1222. doi: 10.1056/NEJMoa1700518. Epub 2017 Mar 18.

7.

Cytomegalovirus-associated thrombocytopenia treated with thrombopoietin receptor agonist.

Simpson JD, Matthews GV, Brighton TA, Joseph JE.

Intern Med J. 2016 Sep;46(9):1096-9. doi: 10.1111/imj.13181.

PMID:
27633469
8.

Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE: A Benefit-Risk Analysis of EINSTEIN-Extension.

Wells PS, Prins MH, Levitan B, Beyer-Westendorf J, Brighton TA, Bounameaux H, Cohen AT, Davidson BL, Prandoni P, Raskob GE, Yuan Z, Katz EG, Gebel M, Lensing AWA.

Chest. 2016 Nov;150(5):1059-1068. doi: 10.1016/j.chest.2016.05.023. Epub 2016 Jun 1.

PMID:
27262225
9.

Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use.

Martinelli I, Lensing AW, Middeldorp S, Levi M, Beyer-Westendorf J, van Bellen B, Bounameaux H, Brighton TA, Cohen AT, Trajanovic M, Gebel M, Lam P, Wells PS, Prins MH.

Blood. 2016 Mar 17;127(11):1417-25. doi: 10.1182/blood-2015-08-665927. Epub 2015 Dec 22.

10.

Paris-Trousseau thrombocytopenia is phenocopied by the autosomal recessive inheritance of a DNA-binding domain mutation in FLI1.

Stevenson WS, Rabbolini DJ, Beutler L, Chen Q, Gabrielli S, Mackay JP, Brighton TA, Ward CM, Morel-Kopp MC.

Blood. 2015 Oct 22;126(17):2027-30. doi: 10.1182/blood-2015-06-650887. Epub 2015 Aug 27.

11.

Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE study.

Weitz JI, Bauersachs R, Beyer-Westendorf J, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Holberg G, Kakkar A, Lensing AW, Prins M, Haskell L, van Bellen B, Verhamme P, Wells PS, Prandoni P; EINSTEIN CHOICE Investigators.

Thromb Haemost. 2015 Aug 31;114(3):645-50. doi: 10.1160/TH15-02-0131. Epub 2015 May 21.

PMID:
25994838
12.

Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials.

Prins MH, Lensing AW, Brighton TA, Lyons RM, Rehm J, Trajanovic M, Davidson BL, Beyer-Westendorf J, Pap ÁF, Berkowitz SD, Cohen AT, Kovacs MJ, Wells PS, Prandoni P.

Lancet Haematol. 2014 Oct;1(1):e37-46. doi: 10.1016/S2352-3026(14)70018-3. Epub 2014 Sep 28.

PMID:
27030066
13.

Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration.

Simes J, Becattini C, Agnelli G, Eikelboom JW, Kirby AC, Mister R, Prandoni P, Brighton TA; INSPIRE Study Investigators (International Collaboration of Aspirin Trials for Recurrent Venous Thromboembolism).

Circulation. 2014 Sep 23;130(13):1062-71. doi: 10.1161/CIRCULATIONAHA.114.008828. Epub 2014 Aug 25.

PMID:
25156992
14.

Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin.

Davidson BL, Verheijen S, Lensing AW, Gebel M, Brighton TA, Lyons RM, Rehm J, Prins MH.

JAMA Intern Med. 2014 Jun;174(6):947-53. doi: 10.1001/jamainternmed.2014.946.

PMID:
24733305
15.

Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies.

Prins MH, Lensing AW, Bauersachs R, van Bellen B, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Raskob GE, Berkowitz SD, Wells PS; EINSTEIN Investigators.

Thromb J. 2013 Sep 20;11(1):21. doi: 10.1186/1477-9560-11-21.

16.

Aspirin for preventing venous thromboembolism.

Brighton TA, Eikelboom JW, Simes J.

N Engl J Med. 2013 Feb 21;368(8):773. doi: 10.1056/NEJMc1215492. No abstract available.

PMID:
23425172
17.

Low-dose aspirin for preventing recurrent venous thromboembolism.

Brighton TA, Eikelboom JW, Mann K, Mister R, Gallus A, Ockelford P, Gibbs H, Hague W, Xavier D, Diaz R, Kirby A, Simes J; ASPIRE Investigators.

N Engl J Med. 2012 Nov 22;367(21):1979-87. doi: 10.1056/NEJMoa1210384. Epub 2012 Nov 4.

18.

Validation of whole blood impedance aggregometry as a new diagnostic tool for HIT: results of a large Australian study.

Morel-Kopp MC, Tan CW, Brighton TA, McRae S, Baker R, Tran H, Mollee P, Kershaw G, Joseph J, Ward C; ASTH Clinical Trials Group.

Thromb Haemost. 2012 Mar;107(3):575-83. doi: 10.1160/TH11-09-0631. Epub 2012 Jan 11.

PMID:
22234599
19.

The direct factor Xa inhibitor rivaroxaban.

Verma AK, Brighton TA.

Med J Aust. 2009 Apr 6;190(7):379-83.

PMID:
19351313
20.

Platelet function testing in uraemic patients.

Ho SJ, Gemmell R, Brighton TA.

Hematology. 2008 Feb;13(1):49-58. doi: 10.1179/102453308X315834.

PMID:
18534067
21.

Consensus guidelines on anti-beta 2 glycoprotein I testing and reporting.

Wong RC, Favaloro EJ, Adelstein S, Baumgart K, Bird R, Brighton TA, Empson M, Gillis D, Hendle MJ, Laurent R, Mallon D, Pollock W, Smith S, Steele RH, Wilson RJ.

Pathology. 2008 Jan;40(1):58-63.

PMID:
18038317
22.

Ximelagatran: direct thrombin inhibitor.

Ho SJ, Brighton TA.

Vasc Health Risk Manag. 2006;2(1):49-58. Review.

23.

Once-daily enoxaparin in the outpatient setting versus unfractionated heparin in hospital for the treatment of symptomatic deep-vein thrombosis.

Chong BH, Brighton TA, Baker RI, Thurlow P, Lee CH; ASTH DVT Study Group.

J Thromb Thrombolysis. 2005 Jun;19(3):173-81.

PMID:
16082604
24.

The direct thrombin inhibitor melagatran/ximelagatran.

Brighton TA.

Med J Aust. 2004 Oct 18;181(8):432-7. Review.

PMID:
15487959
25.

Increased platelet-derived microparticles in the coronary circulation of percutaneous transluminal coronary angioplasty patients.

Craft JA, Masci PP, Roberts MS, Brighton TA, Garrahy P, Cox S, Marsh NA.

Blood Coagul Fibrinolysis. 2004 Sep;15(6):475-82.

PMID:
15311156
26.

Non-valvular atrial fibrillation and stroke: implications for nursing practice and therapeutics.

Davidson P, Rees DM, Brighton TA, Enis J, McCrohon J, Elliott D, Cockburn J, Paull G, Daly J.

Aust Crit Care. 2004 May;17(2):65-73. Review.

PMID:
15218819
27.

Platelet activation in the hypertensive disorders of pregnancy.

Harlow FH, Brown MA, Brighton TA, Smith SL, Trickett AE, Kwan YL, Davis GK.

Am J Obstet Gynecol. 2002 Sep;187(3):688-95.

PMID:
12237649
28.

The clinical significance of antiphospholipid antibodies in patients without autoimmune disease.

Brighton TA, Chesterman CN.

Aust N Z J Med. 2000 Dec;30(6):693-703. Review. No abstract available.

PMID:
11198577
29.

Recent insights into antiphospholipid antibody-mediated thrombosis.

Field SL, Brighton TA, McNeil HP, Chesterman CN.

Baillieres Best Pract Res Clin Haematol. 1999 Sep;12(3):407-22. Review.

PMID:
10856978
30.

Microheterogeneity of beta-2 glycoprotein I: implications for binding to anionic phospholipids.

Brighton TA, Dai YP, Hogg PJ, Chesterman CN.

Biochem J. 1999 May 15;340 ( Pt 1):59-67.

31.
32.

Beta 2-glycoprotein I in thrombosis: evidence for a role as a natural anticoagulant.

Brighton TA, Hogg PJ, Dai YP, Murray BH, Chong BH, Chesterman CN.

Br J Haematol. 1996 Apr;93(1):185-94.

PMID:
8611459
33.

Antiphospholipid antibodies and thrombosis.

Brighton TA, Chesterman CN.

Baillieres Clin Haematol. 1994 Sep;7(3):541-57. Review.

PMID:
7841600

Supplemental Content

Loading ...
Support Center